Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

ct Revenue $17.1 $9.1 $48.6 $27.6

Contract Revenue $0.5 $0.5 $2.0 $1.3

License Revenue $0.1 $1.2 $0.1 $1.5

Non-GAAP Total Revenue $17.7 $10.8 $50.7 $30.4

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Product Gross Margin

Gross Margin on GAAP Basis 51% 34% 53% 37%

Gross Margin from Deferred Revenue

from sales of Trofile assays to

Pfizer 4% 3% 4% 2%

Gross Margin on Non-GAAP Basis 55% 37% 57% 39%

We believe that the foregoing presentation of these Non-GAAP financial measures will enable users of our financial statements to compare Non-GAAP measures with relevant GAAP measures in all periods presented and better understand the matching of revenue and expense. Any Non-GAAP financial measure used by us should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... As part of its ongoing efforts to improve ... for patients diagnosed with scoliosis, Axial Biotech, Inc., a ... diagnostic technologies, today announced that it has signed a ... . The agreement focuses on providing ...
... University of Manchester by Professor Andre Geim and Professor Kostya ... is already being used in such varied applications as touch ... are presenting the vast potential of the wonder material at ... (5 July 2010). The display aims to ...
... 5, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... announced Laszlo Radvanyi, Ph.D., an Associate Professor in ... the University of Texas MD Anderson Cancer Center ... Advisory Board.  MD Anderson is one of the ...
Cached Biology Technology:Axial Biotech Signs Agreement With Shriners Hospital for Children 2Axial Biotech Signs Agreement With Shriners Hospital for Children 3The wonders of graphene on display 2Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board 2Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board 3
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... tuberculosis drug may be effective against not only multi drug-resistant ... compound to treat the latent stage of infection as well. ... Biodefense Research Meeting. , "The class of which this compound ... from any other drug currently used to treat tuberculosis. ...
... raged over whether organic compounds and tiny globules of ... 84001 were processed by living creatures from the Red ... scrutiny ever since. Scientists at the Carnegie Institution's Geophysical ... how material associated with carbonate globules was created using ...
... stem cells may be free of the ethical concerns that ... scientific challenges. Chief among these is the doggedness with which ... isolated from the body. This makes it nearly impossible for ... stem cells are so rare, that makes it difficult to ...
Cached Biology News:Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2Relic of life in that Martian meteorite? A fresh look 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3
Request Info...
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
Request Info...
Biology Products: